Across TCGA pan-cancer cohorts, ATAD3A mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ATAD3A data layer compared with 24 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher ATAD3A mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ATAD3A expression acts as an unfavorable survival marker.

CCRCC, PDAC, and LUAD are the cancer types where ATAD3A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	III,IV	0.105	0.928	.003	44	view →
PDAC	OS	Quartile	All	0.350	0.579	.004	14	view →
LUAD	OS	Tertile	All	0.612	0.986	.031	4	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: ATAD3A tumor-vs-normal RNA expression · all ATAD3A data types